REFERENCES
- Alpert MA. Cardiovascular factors influencing survival in dialysis patients. Adv Perit Dial. 1996; 12: 110–119
- Prichard S, Sniderman A, Cianflone K, Marpole D. Cardiovascular disease in peritoneal dialysis. Perit Dial Int. 1996, Suppl. 1: S19–S22
- Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet. 1993; 342: 1076–1079
- Saigo M, Hsue PY, Waters DD. Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis. 2004; 46: 524–538
- White JG. Platelets and atherosclerosis. Eur J Clin Invest. 1994; 24(Suppl. 1)25–29
- Dahlblack B, Carlsson M, Svensson PJ. Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993; 90: 1004–1008
- Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost. 1999; 25: 167–172
- Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med. 2002; 126: 1281–1295
- Opatrny K, Jr, Zemanova P, Opatrna S, Vit L. Fibrinolysis in chronic renal failure, dialysis and renal transplantation. Ann Transplant. 2002; 7: 34–43
- Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron. 1997; 76: 56–61
- Yorioka N, Masaki T, Ito T, et al. Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis. Int J Artif Organs. 2000; 23: 27–32
- Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Perit Dial Int. 2001; 21: 158–165
- Jones CL, Andrew M, Eddy A, O'Neil M, Shalom NI, Balfe JW. Coagulation abnormalities in chronic peritoneal dialysis. Pediatr Nephrol. 1990; 4: 152–155
- Canavese C, Stratta P, Pacitti A, et al. Impaired fibrinolysis in uremia: Partial and variable correction by four different dialysis regimens. Clin Nephrol. 1982; 17: 82–89
- Gries E, Kopp J, Thomae U, Kuhlmann H. Relation of intraperitoneal and intravascular coagulation and fibrinolysis related antigens in peritoneal dialysis. Thromb Haemostas. 1990; 63: 356–360
- Tomura S, Nakamura Y, Doi M, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator inhibitor-1 and lipid as cardiovascular risk factors in chronic hemodialysis and continuous peritoneal dialysis patients. Am J Kidney Dis. 1996; 27: 848–854
- Narayanana S, Hamasaki N. Current concepts of coagulation and fibrinolysis. Adv Clin Chem. 1998; 33: 133–168
- Genton E. Primary hypercoagulable state. Cardiovasc Clin. 1992; 22: 19–26
- Gordge MP, Faint RW, Rylance PB, Ireland H, Lane DA, Neild GH. Plasma D dimmer: A useful marker of fibrin breakdown in renal failure. Thromb Haemostas. 1989; 61: 520–522
- Irish A. Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis. 1998; 137: 133–139
- Sabo RS, Bartoli F, Apitz-Castro R. In vivo platelet hyperreactivity, another risk factor for patients under continuous ambulatory peritoneal dialysis. Nephron. 1988; 49: 228–230
- Sokunbi DOB, Wadhwa NK, Suh H. Vascular disease outcome and thrombocytosis in diabetics and nondiabetic end-stage renal disease patients on peritoneal dialysis. Adv Perit Dial. 1994; 10: 77–80
- Tassies D, Reverter JC, Cases A, et al. Reticulated platelets in uremic patients: Effect of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Hematol. 1995; 50: 161–166